புதியது நிறுவனங்கள் படைப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புதியது நிறுவனங்கள் படைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புதியது நிறுவனங்கள் படைப்பு Today - Breaking & Trending Today

Investors Dump VMware and Dell Shares as Intel Steals Away Pat Gelsinger

Intel
had snatched away
VMware
CEO Pat Gelsinger to replace Bob Swan and fix the troubled chip giant is weighing heavily on shares of both VMware and
Dell Technologies,
which has an 80.6% stake in the company.
Last year, Dell (ticker: DELL) confirmed press reports that it was considering spinning off its VMware stake to current Dell holders. In such a transaction, VMware (VMW) would likely pay a large cash dividend back to Dell that the PC maker would then use to reduce its substantial debt load.
Now, with VMware losing its iconic leader, there are concerns on Wall Street about VMware’s valuation. Keep in mind that the value of Dell’s stake in VMware is almost equal to Dell’s entire market capitalization. ....

Rajiv Ramaswami , Steve Ballmer , Michael Dell , Pat Gelsinger , Paul Otellini , Brian Krzanich , Ericj Savitz , Bob Swan , Zane Rowe , Satya Nadella , Kara Swisher , Keith Bachman , Jason Ader , Ajay Singh , William Blair , Dell Technologies , Wall Street , Market Perform , Pure Storage , Primary Metals , Non Ferrous Metals , Computers Consumer Electronics , Desktop Computers , Applications Software , Computer Services , Cloud Computing ,

Why Walmart Is Creating a Fintech Start-Up

Order Reprints
Text size
People walking outside a Walmart a store in Washington, D.C.
Nicholas Kamm/AFP via Getty Images
Walmart
stock is rising following the news that the retail giant is pushing into fintech with its latest partnership, the latest in a string of moves diversifying away from its core business.
Walmart (ticker: WMT) announced on Monday that it would create a fintech start-up with Ribbit Capital, a backer of Robinhood and Credit Karma. The new company, which will be majority owned by Walmart, aims to “deliver tech-driven financial experiences tailored to Walmart s customers and associates.”
Walmart was up 1.5%, to $149.44, in trading Tuesday. ....

United States , America Robert Ohmes , Teresa Rivas , Dc Nicholas Kamm , John Zolidis , Getty Images , Ribbit Capital , Robert Ohmes , Walmart Payments , Quo Vadis Capital President John Zolidis , Retail Wholesale , Mixed Retailing , Shopping Malls Superstores , Business Consumer Services , Financial Services , Financial Technology , Shell Company , Corporate Changes , Corporate Strategy Planning , Analysts 39 Comments Recommendations , Corporate Industrial News , Entrepreneurs Startups , New Companies Creation , Small Medium Businesses , Content Types , Factiva Filters ,

IAC Shares Rally as Vimeo Growth Accelerates Ahead of Spinoff

Nopparat Khokthong/Dreamstime.com
IAC/InterActiveCorp
shares were trading higher Tuesday after the internet holding company announced a strong financial update, and Wall Street responded with positive commentary on the stock.
IAC (ticker: IAC) has been issuing monthly financial updates on all of its business lines, and the December update included positive signs from several of its businesses.
Most important, the company said that revenue at Vimeo, a provider of cloud-based video editing tools, rose 57%, accelerating from 54% growth in November and 49% in October. Subscribers were up 24% for the second straight month, increasing from 22% in October, 21% in September and 19% in August. ....

United Kingdom , Nopparat Khokthong Dreamstime , Ericj Savitz , Brian Fitzgerald , Brent Thill , Ask Media Group , Wells Fargo , Wall Street , Cory Carpenter , Diversified Holding Companies , Gambling Industries , Business Consumer Services , Media Content Distribution , E Commerce , Online Service Providers , Leisure Arts Hospitality , Media Entertainment , Streaming Services , Corporate Changes , Corporate Strategy Planning , Financial Performance , Analysts 39 Comments Recommendations , Ownership Changes , Corporate Actions , Corporate Industrial News , New Companies Creation ,

Bluebird Bio to Spin Off Cancer-Drug Unit

Jan. 11, 2021 5:30 am ET
Bluebird Bio Inc., a biotech pioneer in the field of gene therapies, plans to split itself in two later this year, spinning off its cancer-drug unit into a new, publicly traded company so it can focus on rare diseases.
Bluebird Chief Executive Nick Leschly will helm the new cancer company and assume a new position as executive chairman of Bluebird. Andrew Obenshain, currently Bluebird’s president of severe genetic diseases, will become its chief executive, the company said.
The separation is expected to close in the fourth quarter, the company said.
“We built this powerful product engine, and the question is: ‘What is the best way to think about the next five to 10 years?’ ” Mr. Leschly said in an interview. “We don’t believe the past is the best way to head into the future.” ....

United Kingdom , Andrew Obenshain , Nick Leschly , Bluebird Bio Inc , Chief Executive Nick Leschly , Healthcare Life Sciences , Corporate Changes , Corporate Strategy Planning , Ownership Changes , Management Moves , Corporate Actions , Corporate Industrial News , New Companies Creation , Senior Level Management , Political General News , Gene Cell Therapy , Medical Conditions , Medical Treatments Procedures , Content Types , Factiva Filters , C Ampe Executive News Filter , C Ampe Industry News Filter , Wsj Pro Com , Bluebird Bio , Corporate Strategy , Industrial News ,

Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs

Shares of the gene-therapy biotech
bluebird bio
have tumbled in recent months, with the stock dropping 46.4% over the past year as the S&P 500 Health Care sector index has climbed 14.2%.
Now, the company is trying something entirely different in an effort to stop the downward spiral. In a move announced Monday morning, bluebird (ticker: BLUE) said it planned to split into two public companies by the end of the year. One will focus on rare diseases and the other will work on treating cancer.
“After careful strategic review, it is clear to us that the two businesses are best served by independent leadership and teams to drive distinct strategic and operational objectives,” said the company’s CEO, Nick Leschly, in a statement. ....

Josh Nathan Kazis , Bristol Myers Squibb , Nick Leschly , Drug Administration , Health Care , Wall Street , Sarepta Therapeutics , Biomarin Pharmaceutical , Healthcare Life Sciences , Corporate Changes , Corporate Strategy Planning , Financial Performance , Analysts 39 Comments Recommendations , Share Price Movement Disruptions , Ownership Changes , Corporate Actions , Corporate Industrial News , New Companies Creation , Political General News , Medical Conditions , Equity Markets , Commodity Financial Market News , Content Types , Factiva Filters , C Ampe Exclusion Filter , C Ampe Industry News Filter ,